METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Four-Drug cocktail tame pancreatic cancer? a Real-World trial seeks answers
Disease control Recruiting nowThis study follows about 70 people with metastatic pancreatic cancer who are receiving NalIriFOx as their first treatment. Researchers are collecting real-world data to see how well the drug combination controls the disease and what side effects occur. The goal is to understand w…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Hellenic Cooperative Oncology Group • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New PET tracers aim to light up Hard-to-See cancers
Diagnosis Recruiting nowThis early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jul 30, 2026 00:00 UTC